Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmony Outcomes trial of albiglutide for cardiovascular outcomes in type 2 diabetes
NL-OMON45225Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Albiglutide added to standard therapy with Placebo added to standard therapy (2 arms). Primary endpoint: Time to first major adverse cardiovascular event. Started Jul 2015; status: active, not recruiting.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON45225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45225.